• 1
    Neuhaus P, Nashan B, Clavien PA, Kittur D, Salizzoni M, Rimola A, et al. Basiliximab reduces the rate and severity of acute rejection in adult liver transplant recipients [abstract 26]. Transplant 2000, Chicago, IL, May 13–17, 2000.
  • 2
    Nashan B, Neuhaus P, Clavien PA, Kittur D, Salizzoni M, Rimola A, et al. Basiliximab reduces the rate/severity of acute rejection in adult liver transplant recipients [abstract 0292]. International Congress of the Transplantation Society, Rome, Italy, August 27-September 1, 2000.
  • 3
    Hotta SS. Assessment of liver transplantation. Health Technol Assess 1990; 1:1.
  • 4
    Nelson PW, Cosimi AB, Delmonico FL, Rubin R, Tolkoff-Rubin N, Fang L, Russell P. Anti-thymocyte globulin as the primary treatment for renal allograft rejection. Transplantation 1983; 36:587589.MEDLINE
  • 5
    Ortho Multicentre Transplant Study Group. A randomised clinical trial of OKT3 monoclonal antibody for the rejection of cadaveric renal transplants. N Engl J Med 1985; 313:337342.MEDLINE
  • 6
    Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: Results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 5(suppl):S107S114.MEDLINE
  • 7
    Sheiner PA, Schwartz ME, Mor E, Schluger L, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early reoccurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21:3034.MEDLINE
  • 8
    Gane EJ, Naoumov NV, Qian KP, Mondelli M, Maertens G, Portmann B, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110:167177.MEDLINE
  • 9
    Fong TL, Valinluck B, Govindarajan S, Charboneau F, Adkins R, Redeker A. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994; 107:196199.MEDLINE
  • 10
    Kupiec-Weglinski JW, Diamantstein T, Tilney NL. Interleukin-2 receptor-targeted therapy—Rationale and applications in organ transplantation. Transplantation 1988; 46:785792.MEDLINE
  • 11
    Soulillou JP. Relevant targets for therapy with monoclonal antibodies in allograft transplantation. Kidney Int 1994; 46:540553.MEDLINE
  • 12
    Nashan B, Schlitt HJ, Schwinzer R, Ringe B, Kuse E, Tusch G, et al. Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplanted patients. Transplantation 1996; 61:546554.MEDLINE
  • 13
    Langrehr JM, Nüssler N, Neumann U, Guckelberger O, Lohmann R, Radtke A, et al. A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation. Transplantation 1997; 63:17721781.MEDLINE
  • 14
    Neuhaus P, Bechstein W, Blumhardt G, Wiens M, Lemmens P, Langrehr J, et al. Comparison of quadruple immunosuppression after liver transplantation with ATG or IL-2 receptor antibody. Transplantation 1993; 55:13201327.MEDLINE
  • 15
    Soulillou JP, Cantarovich D, Le Mauff B, Giral M, Robillard N, Hourmant M, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322:11751182.MEDLINE
  • 16
    Kupiec-Weglinski JW, Hahn HJ, Kirkman RL, Volk HD, Mouzaki A, DiStefano R, et al. Cyclosporine potentiates the immunosuppressive effects of anti-interleukin-2 receptor monoclonal antibody therapy. Transplant Proc 1988; 20:207.MEDLINE
  • 17
    Amlot PL. The clinical and experimental use of monoclonal antibodies to the IL-2 receptor. In: ChatenoudL (ed). Monoclonal antibodies in transplantation. Austin: Landes, 1995: 5398.
  • 18
    Amlot PL, Rawlings E, Fernando ON, Griffin P, Heinrich G, Schreier M, et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995; 60:748755.MEDLINE
  • 19
    Kovarik JM, Breidenbach T, Gerbeau C, Korn A, Schmidt A-G, Nashan B. Disposition and immunodynamics of basiliximab in liver allograft recipients. Clin Pharmacol Ther 1998; 64:6672.MEDLINE
  • 20
    Nashan B, Moore R, Amlot P, Schmidt A-G, Abeywickrama K, Soulillou J-P. Randomised trial of basiliximab versus placebo for control of acute rejection in renal allograft patients. Lancet 1997; 350:11931198.MEDLINE
  • 21
    Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation 1999; 67:276284.MEDLINE
  • 22
    Anonymous. Good clinical practice for trials on medicinal products in the European Community. Brussels, Belgium: CPMP Working Party on Safety of Medicinal Products, 1990.
  • 23
    Anonymous. Recommendations guiding physicians in biomedical research involving human subjects. Helsinki, amended Tokyo 1975, Venice 1983, Hong Kong 1989. Ferney-Voltaire, France: World Medical Association, 1964.
  • 24
    Peyregne V, Ducerf C, Adham M, de la Roche E, Berthoux N, Bancel B, et al. De novo cancer after orthotopic liver transplantation. Transplant Proc 1998; 30:14841485.MEDLINE
  • 25
    Petrovic LM, Villamil FG, Vierling JM, Makowka L, Geller SA. Comparison of histopathology in acute allograft rejection and recurrent hepatitis C infection after liver transplantation. Liver Transpl Surg 1997; 3:398406.MEDLINE